Device Trial Radar · NCT06237348
Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH
Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Dec 1, 2023
Primary completion
Dec 30, 2024
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Physio-AssistNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Medical University of Lodz; University Hospital in Krakow
- First posted
- Feb 1, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot RCT will assess benefits of Simeox technology on lung function, respiratory symptoms, health-related quality of life, subjective efficiency, device adherence at home, Patient satisfaction, tolerance, safety, and telecare feasibility.
Conditions
- Non-cystic Fibrosis Bronchiectasis
- Chronic Mucus Hypersecretion
Interventions
SimeoxDevice
Daily airway clearance therapy at home during 2 months
ControlCombination product
Daily airway clearance therapy at home during 2 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- To describe the evolution in Self-reported home adherence from baseline (hospital discharge) during follow-upTime frame: 2 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Jagiellonian University Medical College
Krakow, Poland
N. Barlicki University Hospital No 1
Lodz, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.